Induction of complete remission using single agent clofarabine in a patient with primary refractory acute myeloblaste leukemia

Leukemia and Lymphoma

Volumn 44, Issue 12, 2003, Pages 2135-2136

  Douer, Dan ^a   Watkins, Kristy ^a   Levine, Alexandra M ^a   Weiss, Jane M ^b   Marshall, Lynette C ^b   Craig, Adam R ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Ilex Oncology Inc   (United States)

Author keywords

AML; Clofarabine; Primary refractory acute myloblaste leukemia; Purine nucleoside

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CLOFARABINE; CYTARABINE; ETOPOSIDE; IDARUBICIN; LIVER ENZYME; MITOXANTRONE; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CASE REPORT; DRUG DESIGN; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA REMISSION; LIVER DYSFUNCTION; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE;

ADENINE NUCLEOTIDES; ADULT; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; NUCLEOSIDES; PROGNOSIS; PURINES; REMISSION INDUCTION;

EID: 0242635583     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000111099     Document Type: Article

References (6)

1. Golub, T.R. and Arceci, R.J. (2002) "Acute myelogenous leukemia", In: Pizzo, P.A. and Poplack, D.G., eds, Principles and Practices of Pediatric Oncology, 4th Ed. (Lippincott Williams and Wilkins, Philadelphia) pp 545-589.
2. Bloomfield, C.D. and Caligiuri, M.A. (2001) "Leukemias", In: DeVita, V.T., Jr, Hellman, S. and Rosenberg, S.A., eds, Principles and Practice of Oncology, 6th Ed. (Lippincott Williams and Wilkins, Philadelphia) pp 2389-2509.
3. Appelbaum, F.R., Rowe, J.M., Radich, J. and Dick, J.E. (2001) "Acute myeloid leukemia", In: Schechter, G., Broudy, V. and Williams, M., eds, Hematology 2001: Education Program Book of the American Society of Hematology Annual Meeting (Orlando, 2001) (American Society of Hematology, Washington) pp 62-86.
4. Gorin, N.C., Estey, E., Jones, R.J., Jones, R.J., Levitsky, H.I., Borrello, I. and Slavin, S. (2000) "New development in the therapy of acute myelocytic leukemia", In: Schechter, G.P., Berliner, N. and Telen, M.J., eds, Hematology 2000: Education Program Book of the American Society of Hematology Annual Meeting (San Francisco, 2000) (American Society of Hematology, Washington) pp 69-89.
5. Cheson, B.D., Vena, D.A., Foss, F.M. and Sorensen, J.M. (1994) "Neurotoxicity of purine analogs: a review", Journal of Clinical Oncology 12(10), 2216-2228.
6. Cortes, J.E., Gandhi, V., Plunkett, W., Keating, M., Faderl, S., O'Brien, S., Giles, F., Garcia-Manero, G., Thomas, D., Du, M., Davis, J., Craig, A., Estey, E. and Kantarjian, H. (2002) "Clofarabine {2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine} is active for patients with refractory or relapsed acute leukemias, myelodysplastic syndromes (MDS) and chronic myeloid leukemia in blast phase (CML-BP)", Blood 100(Suppl. 1), 197a.